Other adverse events in people taking macrolide antibiotics showed no clear difference in hearing loss compared with placebo (low certainty).
Other adverse events in people taking macrolide antibiotics may leads to higher taste disturbance compared with placebo (low certainty).
It is very uncertain whether other adverse events in people taking macrolide antibiotics changes hepatobiliary disorders compared with placebo (very low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in treatment response at 12 months: complete remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).